LRMR
What one share of Larimar Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide (“CPP”) technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin (“FXN”), an essential protein, to the mitochondria of patients with Friedreich's ataxia (“FA”).
Larimar Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.69 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.53 |
| Cash and investments | $0.89 |
| Book value | $1.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.00 | −$2.12 | $0.02 | −$1.93 | — | $4.45 |
| 2017 | $0.00 | −$1.90 | $0.00 | −$1.60 | — | $2.85 |
| 2018 | $0.00 | −$1.90 | $0.00 | −$1.60 | — | $0.08 |
| 2019 | $0.00 | −$3.80 | $0.01 | −$3.74 | — | −$0.11 |
| 2020 | — | −$3.58 | $0.01 | −$3.56 | — | $5.84 |
| 2021 | — | −$2.95 | $0.02 | −$2.47 | — | $3.64 |
| 2022 | — | −$1.37 | $0.00 | −$1.07 | — | $2.56 |
| 2023 | — | −$0.84 | $0.00 | −$0.77 | — | $1.86 |
| 2024 | — | −$1.32 | $0.01 | −$1.16 | — | $2.69 |
| 2025 | — | −$1.19 | $0.00 | −$0.81 | — | $0.94 |